

COMPANY OVERVIEW

Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create viable antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and clinical-stage antiviral therapeutics that target the replication process of norovirus, influenza, coronavirus and hepatitis C virus.

RECENT NEWS

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Jun 3 2026, 7:00 AM EDT

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

May 26 2026, 8:00 AM EDT

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

May 15 2026, 8:00 AM EDT

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	11.31m
Last Price	\$0.82
52-Week Range	\$0.76 - \$2.67

07/31/2026 08:00 PM EDT

INVESTOR RELATIONS

Alliance Advisors IR
Bruce Voss
T: 310-691-7104
bvoss@allianceadvisors.com

MANAGEMENT TEAM

James Sapirstein

Chief Executive Officer

Sam Lee, Ph.D.

President and Chief Scientific Officer

James J. Martin

Chief Financial Officer

COCRYSTAL PHARMA, INC.

19805 North Creek Parkway
Bothell, WA 98011
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.